Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need

Executive Summary

New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need. 

You may also be interested in...



Drug Discount Programs Create More Cloud In Quest For Transparency

Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices. 

Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021

Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.

Copay Coupons May Skew Medicare Part B Reimbursement, GAO Says

Manufacturer-generated average sales price reports used by CMS to set Part B drug reimbursement doesn’t reflect net price after coupons.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel